share_log

Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease

Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease

Acumen Pharmicals宣布在早期阿尔茨海默氏病的Sabirnetug(ACU193)的ALTITUDE-AD 2期临床试验中为首位患者服药
Benzinga ·  05/08 08:28

Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease

Acumen Pharmicals宣布在早期阿尔茨海默氏病的Sabirnetug(ACU193)的ALTITUDE-AD 2期临床试验中为首位患者服药

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发